aluates Reports

$ 0.0

Global RNA-Targeted Small Molecule Drugs Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-33D11477

Global RNA Targeted Small Molecule Drugs Market Research Report 2022

BUY CHAPTERS

Global RNA-Targeted Small Molecule Drugs Market Research Report 2025

Code: QYRE-Auto-33D11477

Report

March 2025

Pages:88

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

Anima Biotech

RNA-Targeted Small Molecule Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

RNA-Targeted Small Molecule Drugs Market

The global market for RNA-Targeted Small Molecule Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for RNA-Targeted Small Molecule Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Targeted Small Molecule Drugs.

The RNA-Targeted Small Molecule Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNA-Targeted Small Molecule Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the RNA-Targeted Small Molecule Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of RNA-Targeted Small Molecule Drugs Market Report

Report Metric	Details
Report Name	RNA-Targeted Small Molecule Drugs Market
CAGR	5%
Segment by Type	mRNA Translation Regulation RNA Splicing Modification Direct RNA Targeting Indirect RNA Targeting - Epitranscriptomics
Segment by Application	SMA Oncology Lung Fibrosis Huntington's Disease Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics, Expansion Therapeutics, Gotham Therapeutics, H3 Biomedicine, Ribometrix, Skyhawk Therapeutics, STORM Therapeutics, Twentyeight-Seven Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecule Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the RNA-Targeted Small Molecule Drugs Market report?

Ans: The main players in the RNA-Targeted Small Molecule Drugs Market are Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics, Expansion Therapeutics, Gotham Therapeutics, H3 Biomedicine, Ribometrix, Skyhawk Therapeutics, STORM Therapeutics, Twentyeight-Seven Therapeutics

What are the Application segmentation covered in the RNA-Targeted Small Molecule Drugs Market report?

Ans: The Applications covered in the RNA-Targeted Small Molecule Drugs Market report are SMA, Oncology, Lung Fibrosis, Huntington's Disease, Others

What are the Type segmentation covered in the RNA-Targeted Small Molecule Drugs Market report?

Ans: The Types covered in the RNA-Targeted Small Molecule Drugs Market report are mRNA Translation Regulation, RNA Splicing Modification, Direct RNA Targeting, Indirect RNA Targeting - Epitranscriptomics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 mRNA Translation Regulation

1.2.3 RNA Splicing Modification

1.2.4 Direct RNA Targeting

1.2.5 Indirect RNA Targeting - Epitranscriptomics

1.3 Market by Application

1.3.1 Global RNA-Targeted Small Molecule Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 SMA

1.3.3 Oncology

1.3.4 Lung Fibrosis

1.3.5 Huntington's Disease

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global RNA-Targeted Small Molecule Drugs Market Perspective (2020-2031)

2.2 Global RNA-Targeted Small Molecule Drugs Growth Trends by Region

2.2.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 RNA-Targeted Small Molecule Drugs Historic Market Size by Region (2020-2025)

2.2.3 RNA-Targeted Small Molecule Drugs Forecasted Market Size by Region (2026-2031)

2.3 RNA-Targeted Small Molecule Drugs Market Dynamics

2.3.1 RNA-Targeted Small Molecule Drugs Industry Trends

2.3.2 RNA-Targeted Small Molecule Drugs Market Drivers

2.3.3 RNA-Targeted Small Molecule Drugs Market Challenges

2.3.4 RNA-Targeted Small Molecule Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue

3.1.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue (2020-2025)

3.1.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2020-2025)

3.2 Global RNA-Targeted Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by RNA-Targeted Small Molecule Drugs Revenue

3.4 Global RNA-Targeted Small Molecule Drugs Market Concentration Ratio

3.4.1 Global RNA-Targeted Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by RNA-Targeted Small Molecule Drugs Revenue in 2024

3.5 Global Key Players of RNA-Targeted Small Molecule Drugs Head office and Area Served

3.6 Global Key Players of RNA-Targeted Small Molecule Drugs, Product and Application

3.7 Global Key Players of RNA-Targeted Small Molecule Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 RNA-Targeted Small Molecule Drugs Breakdown Data by Type

4.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Type (2020-2025)

4.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Type (2026-2031)

5 RNA-Targeted Small Molecule Drugs Breakdown Data by Application

5.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Application (2020-2025)

5.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America RNA-Targeted Small Molecule Drugs Market Size (2020-2031)

6.2 North America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025)

6.4 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe RNA-Targeted Small Molecule Drugs Market Size (2020-2031)

7.2 Europe RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025)

7.4 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size (2020-2031)

8.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America RNA-Targeted Small Molecule Drugs Market Size (2020-2031)

9.2 Latin America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025)

9.4 Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size (2020-2031)

10.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche RNA-Targeted Small Molecule Drugs Introduction

11.1.4 Roche Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis RNA-Targeted Small Molecule Drugs Introduction

11.2.4 Novartis Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 PTC Therapeutics

11.3.1 PTC Therapeutics Company Details

11.3.2 PTC Therapeutics Business Overview

11.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.3.4 PTC Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.3.5 PTC Therapeutics Recent Development

11.4 Biogen

11.4.1 Biogen Company Details

11.4.2 Biogen Business Overview

11.4.3 Biogen RNA-Targeted Small Molecule Drugs Introduction

11.4.4 Biogen Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.4.5 Biogen Recent Development

11.5 Accent Therapeutics

11.5.1 Accent Therapeutics Company Details

11.5.2 Accent Therapeutics Business Overview

11.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.5.4 Accent Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.5.5 Accent Therapeutics Recent Development

11.6 Anima Biotech

11.6.1 Anima Biotech Company Details

11.6.2 Anima Biotech Business Overview

11.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Introduction

11.6.4 Anima Biotech Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.6.5 Anima Biotech Recent Development

11.7 Arrakis Pharmaceuticals

11.7.1 Arrakis Pharmaceuticals Company Details

11.7.2 Arrakis Pharmaceuticals Business Overview

11.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Introduction

11.7.4 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.7.5 Arrakis Pharmaceuticals Recent Development

11.8 Epics Therapeutics

11.8.1 Epics Therapeutics Company Details

11.8.2 Epics Therapeutics Business Overview

11.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.8.4 Epics Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.8.5 Epics Therapeutics Recent Development

11.9 Expansion Therapeutics

11.9.1 Expansion Therapeutics Company Details

11.9.2 Expansion Therapeutics Business Overview

11.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.9.4 Expansion Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.9.5 Expansion Therapeutics Recent Development

11.10 Gotham Therapeutics

11.10.1 Gotham Therapeutics Company Details

11.10.2 Gotham Therapeutics Business Overview

11.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.10.4 Gotham Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.10.5 Gotham Therapeutics Recent Development

11.11 H3 Biomedicine

11.11.1 H3 Biomedicine Company Details

11.11.2 H3 Biomedicine Business Overview

11.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Introduction

11.11.4 H3 Biomedicine Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.11.5 H3 Biomedicine Recent Development

11.12 Ribometrix

11.12.1 Ribometrix Company Details

11.12.2 Ribometrix Business Overview

11.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Introduction

11.12.4 Ribometrix Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.12.5 Ribometrix Recent Development

11.13 Skyhawk Therapeutics

11.13.1 Skyhawk Therapeutics Company Details

11.13.2 Skyhawk Therapeutics Business Overview

11.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.13.4 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.13.5 Skyhawk Therapeutics Recent Development

11.14 STORM Therapeutics

11.14.1 STORM Therapeutics Company Details

11.14.2 STORM Therapeutics Business Overview

11.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.14.4 STORM Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.14.5 STORM Therapeutics Recent Development

11.15 Twentyeight-Seven Therapeutics

11.15.1 Twentyeight-Seven Therapeutics Company Details

11.15.2 Twentyeight-Seven Therapeutics Business Overview

11.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Introduction

11.15.4 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025)

11.15.5 Twentyeight-Seven Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

Anima Biotech

List of Tables

Table 1. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of mRNA Translation Regulation

Table 3. Key Players of RNA Splicing Modification

Table 4. Key Players of Direct RNA Targeting

Table 5. Key Players of Indirect RNA Targeting - Epitranscriptomics

Table 6. Global RNA-Targeted Small Molecule Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global RNA-Targeted Small Molecule Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2020-2025)

Table 10. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2026-2031)

Table 12. RNA-Targeted Small Molecule Drugs Market Trends

Table 13. RNA-Targeted Small Molecule Drugs Market Drivers

Table 14. RNA-Targeted Small Molecule Drugs Market Challenges

Table 15. RNA-Targeted Small Molecule Drugs Market Restraints

Table 16. Global RNA-Targeted Small Molecule Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global RNA-Targeted Small Molecule Drugs Market Share by Players (2020-2025)

Table 18. Global Top RNA-Targeted Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Targeted Small Molecule Drugs as of 2024)

Table 19. Ranking of Global Top RNA-Targeted Small Molecule Drugs Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by RNA-Targeted Small Molecule Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of RNA-Targeted Small Molecule Drugs, Headquarters and Area Served

Table 22. Global Key Players of RNA-Targeted Small Molecule Drugs, Product and Application

Table 23. Global Key Players of RNA-Targeted Small Molecule Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2020-2025)

Table 27. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2026-2031)

Table 29. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2020-2025)

Table 31. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2026-2031)

Table 33. North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. Roche Company Details

Table 49. Roche Business Overview

Table 50. Roche RNA-Targeted Small Molecule Drugs Product

Table 51. Roche Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 52. Roche Recent Development

Table 53. Novartis Company Details

Table 54. Novartis Business Overview

Table 55. Novartis RNA-Targeted Small Molecule Drugs Product

Table 56. Novartis Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 57. Novartis Recent Development

Table 58. PTC Therapeutics Company Details

Table 59. PTC Therapeutics Business Overview

Table 60. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 61. PTC Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 62. PTC Therapeutics Recent Development

Table 63. Biogen Company Details

Table 64. Biogen Business Overview

Table 65. Biogen RNA-Targeted Small Molecule Drugs Product

Table 66. Biogen Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 67. Biogen Recent Development

Table 68. Accent Therapeutics Company Details

Table 69. Accent Therapeutics Business Overview

Table 70. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 71. Accent Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 72. Accent Therapeutics Recent Development

Table 73. Anima Biotech Company Details

Table 74. Anima Biotech Business Overview

Table 75. Anima Biotech RNA-Targeted Small Molecule Drugs Product

Table 76. Anima Biotech Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 77. Anima Biotech Recent Development

Table 78. Arrakis Pharmaceuticals Company Details

Table 79. Arrakis Pharmaceuticals Business Overview

Table 80. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product

Table 81. Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 82. Arrakis Pharmaceuticals Recent Development

Table 83. Epics Therapeutics Company Details

Table 84. Epics Therapeutics Business Overview

Table 85. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 86. Epics Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 87. Epics Therapeutics Recent Development

Table 88. Expansion Therapeutics Company Details

Table 89. Expansion Therapeutics Business Overview

Table 90. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 91. Expansion Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 92. Expansion Therapeutics Recent Development

Table 93. Gotham Therapeutics Company Details

Table 94. Gotham Therapeutics Business Overview

Table 95. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 96. Gotham Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 97. Gotham Therapeutics Recent Development

Table 98. H3 Biomedicine Company Details

Table 99. H3 Biomedicine Business Overview

Table 100. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product

Table 101. H3 Biomedicine Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 102. H3 Biomedicine Recent Development

Table 103. Ribometrix Company Details

Table 104. Ribometrix Business Overview

Table 105. Ribometrix RNA-Targeted Small Molecule Drugs Product

Table 106. Ribometrix Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 107. Ribometrix Recent Development

Table 108. Skyhawk Therapeutics Company Details

Table 109. Skyhawk Therapeutics Business Overview

Table 110. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 111. Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 112. Skyhawk Therapeutics Recent Development

Table 113. STORM Therapeutics Company Details

Table 114. STORM Therapeutics Business Overview

Table 115. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 116. STORM Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 117. STORM Therapeutics Recent Development

Table 118. Twentyeight-Seven Therapeutics Company Details

Table 119. Twentyeight-Seven Therapeutics Business Overview

Table 120. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product

Table 121. Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2020-2025) & (US$ Million)

Table 122. Twentyeight-Seven Therapeutics Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. RNA-Targeted Small Molecule Drugs Picture

Figure 2. Global RNA-Targeted Small Molecule Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global RNA-Targeted Small Molecule Drugs Market Share by Type: 2024 VS 2031

Figure 4. mRNA Translation Regulation Features

Figure 5. RNA Splicing Modification Features

Figure 6. Direct RNA Targeting Features

Figure 7. Indirect RNA Targeting - Epitranscriptomics Features

Figure 8. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global RNA-Targeted Small Molecule Drugs Market Share by Application: 2024 VS 2031

Figure 10. SMA Case Studies

Figure 11. Oncology Case Studies

Figure 12. Lung Fibrosis Case Studies

Figure 13. Huntington's Disease Case Studies

Figure 14. Others Case Studies

Figure 15. RNA-Targeted Small Molecule Drugs Report Years Considered

Figure 16. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global RNA-Targeted Small Molecule Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global RNA-Targeted Small Molecule Drugs Market Share by Region: 2024 VS 2031

Figure 19. Global RNA-Targeted Small Molecule Drugs Market Share by Players in 2024

Figure 20. Global Top RNA-Targeted Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Targeted Small Molecule Drugs as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by RNA-Targeted Small Molecule Drugs Revenue in 2024

Figure 22. North America RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America RNA-Targeted Small Molecule Drugs Market Share by Country (2020-2031)

Figure 24. United States RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2020-2031)

Figure 28. Germany RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share by Region (2020-2031)

Figure 36. China RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America RNA-Targeted Small Molecule Drugs Market Share by Country (2020-2031)

Figure 44. Mexico RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2020-2031)

Figure 48. Turkey RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Roche Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 53. PTC Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 54. Biogen Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 55. Accent Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 56. Anima Biotech Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 57. Arrakis Pharmaceuticals Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 58. Epics Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 59. Expansion Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 60. Gotham Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 61. H3 Biomedicine Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 62. Ribometrix Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 63. Skyhawk Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 64. STORM Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 65. Twentyeight-Seven Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions